Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach

Article Article scientifique Article Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach eng 2022-09-01 author Kalonji Pauline Department of Readaptation and Geriatrics, University of Geneva, Geneva, Switzerland. 851177 author Revol Aurélie Suzy Gisèle Palliative Medicine Division and University Hospital Geneva, Geneva, Switzerland. 850855 author Broers Barbara Department of Readaptation and Geriatrics, University of Geneva, Geneva, Switzerland. 28005 Structure enseignement (ENSI) author Ljuslin Michael Jan Alexandre 0000-0002-2386-1749 Palliative Medicine Division and University Hospital Geneva, Geneva, Switzerland. 538816 author Pautex Sophie Marie 0000-0001-7248-3513 Department of Readaptation and Geriatrics, University of Geneva, Geneva, Switzerland. 37604 dept de réadaptation et gériatrie (MIGRG) 200-205 10.1089/pmr.2022.0021 36203714 2689-2820 PMC9531874 https://www.liebertpub.com/doi/10.1089/pmr.2022.0021 Background: A minority of palliative care patients benefit from prescribed cannabinoid-based medicines (CBMs). Objective: The objective of this study was to explore the perceptions, expectations, and experiences of CBM usage among palliative care patients and to evaluate whether and how they may constitute an obstacle to prescription. Design: This is a qualitative study involving semistructured in-depth interviews with 10 patients hospitalized in a palliative care unit in Geneva, Switzerland. The data were analyzed using the interpretative phenomenological analysis method. Results: Semistructured interviews were conducted on 10 patients (average age of 73.3 years), mainly with advanced cancer. Most patients favored CBM use in palliative care and distinguished it from recreational use. Seven themes were identified from patients' perceptions, experiences, and expectations during the interviews: right time to begin CBMs, off-label use, information about side effects, lack of a safe medical framework, costs, relatives, and social acceptance of CBMs. Conclusion: The obstacles described by the patients seem to be surmountable with specific measures at the clinical level. We suggest training health professionals in a palliative care setting, especially in explaining the effects and side effects. CBMs will undoubtedly play a more significant role in palliative care medicine in the years to come. Cannabinoids Medical cannabis Palliative care Patients’ expectations Patients’ experiences Patients’ perceptions Dewey 618.97 65 Département de réadaptation et gériatrie 22B false 436 Médecine palliative 709 Palliative medicine reports 3 1 7bf11fc0-d51c-4be3-a438-c9b451fecefe Article (Published version) Public Article-scientifique-from-crossref.pdf 505806 application/pdf CC BY-4.0 4c0d45bf14ab7c4bad8541a8eae256ea31c5003fff2faaaa061b3df8b70dc66a openAccess Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach	Palliative medicine reports			2022	217	110

Archive ouverte UNIGE

Kalonji, Pauline